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Background: Secretoglobin 1A1 (SCGB 1A1), also called Clara cell secretory protein, is the most abundantly
secreted protein of the airway. The SCGB1A1 gene has been characterized in mammals as a single copy in the
genome. However, analysis of the equine genome suggested that horses might have multiple SCGB1A1 gene
copies. Non-ciliated lung epithelial cells produce SCGB 1A1 during inhalation of noxious substances to counter
airway inflammation. Airway fluid and lung tissue of horses with recurrent airway obstruction (RAO), a chronic
inflammatory lung disease affecting mature horses similar to environmentally induced asthma of humans, have
reduced total SCGB 1A1 concentration. Herein, we investigated whether horses have distinct expressed SCGB1A1
genes; whether the transcripts are differentially expressed in tissues and in inflammatory lung disease; and whether
there is cell specific protein expression in tissues.
Results: We identified three SCGB1A1 gene copies on equine chromosome 12, contained within a 512-kilobase
region. Bioinformatic analysis showed that SCGB1A1 genes differ from each other by 8 to 10 nucleotides, and that
they code for different proteins. Transcripts were detected for SCGB1A1 and SCGB1A1A, but not for SCGB1A1P. The
SCGB1A1P gene had most inter-individual variability and contained a non-sense mutation in many animals,
suggesting that SCGB1A1P has evolved into a pseudogene. Analysis of SCGB1A1 and SCGB1A1A sequences by
endpoint-limiting dilution PCR identified a consistent difference affecting 3 bp within exon 2, which served as a
gene-specific “signature”. Assessment of gene- and organ-specific expression by semiquantitative RT-PCR of 33
tissues showed strong expression of SCGB1A1 and SCGB1A1A in lung, uterus, Fallopian tube and mammary gland,
which correlated with detection of SCGB 1A1 protein by immunohistochemistry. Significantly altered expression of
the ratio of SCGB1A1A to SCGB1A1 was detected in RAO-affected animals compared to controls, suggesting different
roles for SCGB 1A1 and SCGB 1A1A in this inflammatory condition.
Conclusions: This is the first report of three SCGB1A1 genes in a mammal. The two expressed genes code for
proteins predicted to differ in function. Alterations in the gene expression ratio in RAO suggest cell and tissue
specific regulation and functions. These findings may be important for understanding of lung and reproductive
conditions.
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The mammalian airway epithelium is composed of het-
erogeneous cell populations grouped into three main
types according to morphology and function: basal,
ciliated, and secretory cells [1]. Further, eight morpho-
logically defined subtypes are recognized, including non-
ciliated, cuboidal and secretory Clara cells [2]. Clara cells
synthesize the most abundantly secreted protein in the
airway surface fluid, secretoglobin family 1A, member 1
(SCGB 1A1) [3]. The list of names attributed to SCGB
1A1 is extensive and includes Clara Cell Secretory Pro-
tein (CCSP), uteroglobin, blastokinin, Clara cell 10 kDa
protein (CC10), CC16, polychlorinated biphenyl-binding
protein (PCB-BP), and urine protein-1 (UP1). SCGB 1A1
has been ascribed many functions including binding of
lipophilic substances, inhibition of leukocyte recruit-
ment, inhibition of phospholipase A2, and other anti-
inflammatory roles (reviewed in [4,5]).
SCGB 1A1 is consistently expressed at high levels in
the lung of most mammalian species. More specifically,
studies in the horse showed that SCGB 1A1 is detected
in non-ciliated lung epithelial cells, but not in goblet or
ciliated epithelial cells [6]. SCGB 1A1 comprises 2 to
12% of bronchoalveolar lavage (BAL) fluid proteins [7,8],
and is considered to be an important component of pro-
teins protecting the pulmonary epithelium against dele-
terious inhaled environmental substances [9]. It was
previously reported that horses with recurrent airway
obstruction (RAO), an asthma-like chronic inflammatory
condition affecting mature individuals, have ultrastruc-
tural changes in Clara cells [6], decreased lung SCGB1A1
gene expression [6,10] and reduced BAL fluid SCGB
1A1 concentration [6]. Expression of SCGB1A1 has also
variously been described in extra-pulmonary tissues
from diverse species. In horses, SCGB1A1 transcripts
were present in uterine and prostatic tissues and absent
in liver, kidney, heart, spleen, thyroid, pituitary and ad-
renal gland tissues [11].
A single SCGB1A1 gene has been described in the
genome of multiple mammals, including rabbit, rat,
mouse, monkey, and human [12-15]. The general struc-
ture of the SCGB1A1 gene includes two introns and
three exons coding for a small secreted protein of ~70
amino acids. This organizational structure is remarkably
conserved between species; however, the length of the
SCGB1A1 genomic locus fluctuates [12-17]. In horses,
the first reported sequence was described as a unique
cDNA and was ascribed to a single gene [11]. However,
the recent availability of the complete Equus caballus
genome sequence provided evidence of three highly
similar SCGB1A1 gene sequences on chromosome 12,
suggesting the horse has diverged from the “single copy”
SCGB1A1 consensus. Two distinct SCGB 1A1 protein
products were also identified in uterine fluids duringearly pregnancy [18], further implying that more than
one SCGB1A1 gene may be transcribed and translated.
Considering that horses appear to have multiple simi-
lar, but not identical, SCGB1A1 gene copies, and that
total SCGB 1A1 levels are decreased in the lung of
horses with RAO, we hypothesized that SCGB1A1 var-
iants may be differentially expressed and have different
functions. Herein, we report on three distinct copies of
the SCGB1A1 gene in horses. We developed assays to
distinguish each gene, determined tissue- and copy-
specific gene expression, and evaluated cell-specific pres-
ence of the SCGB 1A1 protein. We further determined
that horses with RAO have an abnormal expression ratio
of different SCGB1A1 genes.
Results
Identification and localization of SCGB1A1 genes
Basic Local Alignment Search Tool (BLAST) was used
to determine sequence similarity between the most re-
cent high-quality equine chromosome-12 genomic se-
quence (EquCab2.0; NW_001867370.1) [19] and the
previously described equine SCGB1A1 precursor mRNA
(AY885564.1). Nine BLAST hits were identified at posi-
tions 2788223-2788256 (100% identity, e-value 2-10),
2788555-2788748 (99% identity, e-value 2-95), 2790815-
2790869 (96% identity, e-value 9-19), 2810573- 2810606
(100% identity, e-value 2-10), 2810905-2811098 (99%
identity, e-value 4-97), 2813166- 2813220 (98% identity,
e-value 2-20), 3296852- 3296906 (98% identity, e-value 2-20),
3298978-3299171 (97% identity, e-value 8-89), and 3299470-
3299503 (94% identity, e-value 4-07), consistent with the
presence of three SCGB1A1 gene copies on chromosome
12, each encompassing three exons (hits). The three pre-
dicted copies were contained within a 512-kilobase (kb) re-
gion, with two copies positioned in reverse orientation and
one in forward orientation (Figure 1A).
A partial sequence including a large part of the adjoining
5’ and 3’ non-coding DNA was extracted from the Equ-
Cab2.0 sequence for each predicted copy (~10 kb/se-
quence) and analyzed by multiple sequence alignment.
Bioinformatic analysis confirmed that each gene had com-
parable exon/intron organization, and covered about 2,650
base pairs (bp) of genomic DNA (Figure 1B). A high degree
of pairwise identity (92.7%) was observed in large segments
overlapping the SCGB1A1 coding regions and 8,941 identi-
cal sites (87.8%) were found among the three genes,
suggesting that SCGB1A1 genes developed from an intra-
chromosomal triplication event. The pairwise identity
increased to 97.8% and the number of identical sites rose
to 96.7% upon alignment of the predicted complementary
DNA (cDNA) sequences. However, SCGB1A1 genes dif-
fered from each other by 8 to 10 nucleotides, and were
expected to produce different proteins. Therefore, the dis-
tinct genes were termed SCGB1A1P, SCGB1A1, and
Figure 1 Schematic representation of SCGB1A1 sequencing strategy and enzymatic restriction analysis. (A) The partial genomic sequence
of Equus caballus chromosome 12 (based on EquCab2.0, NW_001867370.1) encompassing the three predicted equine SCGB1A1 genes (red
triangles). SCGB1A1P and SCGB1A1 are in reverse orientation, while SCGB1A1A is in forward orientation. The chromosome 12 region (original bases
2,788,223 to 3,299,503) includes 511,281 bp bordered by the SCGB1A1P stop codon guanine (position 1) and the SCGB1A1A stop codon guanine
(position 511,281). SCGB1A1P is most proximal to the centromere. (B) Predicted structure of an individual SCGB1A1 gene, each containing
approximately 2,650 bp, including 3 small exons (green arrows) and 2 introns. (C) Multiple sequence alignment of the three predicted SCGB1A1
genes. The LR-PCR amplification strategy is outlined in blue. Each primer (blue triangle) is specific for a single copy enabling amplification of
three distinct PCR products (blue line). Exons are displayed in green under the consensus sequence (black). (D) Restriction enzyme digestion
analysis. Non-digested amplicons for SCGB1A1P, SCGB1A1 and SCGB1A1A were 5,559, 6,029 and 5,442 bp in size, respectively. Upon HindIII
digestion, SCGB1A1P was detected by 3166, 1942 and 464 bp, SCGB1A1 by 1942, 1,717, 1563, and 891 bp, and SCGB1A1A by 2675, 1942, and
899 bp fragments. H (red), HindIII restriction site; M, 1 Kb + DNA ladder; ND, Non-digested; D, Digested.
Côté et al. BMC Genomics 2012, 13:712 Page 3 of 14
http://www.biomedcentral.com/1471-2164/13/712SCGB1A1A; with SCGB1A1P located most proximal to the
centromere. These novel sequences were deposited in
GenBank with the following accession numbers: JQ951929,
JQ951930 and JQ951931.
Isolation and characterization of SCGB1A1 genomic
sequences
A long-range (LR)-PCR strategy was developed to amp-
lify individual full-length SCGB1A1P, SCGB1A1, and
SCGB1A1A genomic sequences, using three distinct gene-
specific primer sets (Figure 1C). The size of the differentLR-PCR products ranged from 5.4 to 6.0 kb. Samples from
a total of 24 animals were used for amplification, purifica-
tion, and identification of the SCGB1A1P sequence,
compared to SCGB1A1 and SCGB1A1A sequences,
which were accurately documented by the examination
of 12 sequences due to a reduced amount of poly-
morphisms between individuals analyzed. The identity
of all PCR fragments was further evaluated by restric-
tion enzyme digestion assay (Figure 1D), which con-
firmed presence of three different SCGB1A1 genes in
each animal assessed.
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secreted protein (including exons 2 and 3) was subse-
quently targeted by nested PCR, using the previously
purified LR-PCR products as template (Figure 2A).
Hence, 24, 12 and 12 amplicons were generated in dupli-
cate from SCGB1A1P, SCGB1A1, and SCGB1A1A full-
length sequences, respectively. Each PCR product was
individually analyzed by electrophoresis, purified and
sequenced, using both forward and reverse sequencing.
The resultant 96 SCGB1A1P, 48 SCGB1A1 and 48
SCGB1A1A sequences were subjected to multiple se-
quence alignment. A high level of agreement was found
between the different sequences from each gene, with
pairwise identity consistently greater than 98%. A consen-
sus sequence was determined for SCGB1A1P, SCGB1A1,
and SCGB1A1A (Figure 2B). Bioinformatic analysis
revealed a combination of three non-contiguous single nu-
cleotide differences that conferred a gene-specific “signa-
ture” sequence at positions 150, 175 and 217 on the
cDNA map (Figure 2C). As shown in Figure 2C, differentFigure 2 Characterization of SCGB1A1 genomic sequences. (A) A partia
purified LR-PCR products as template. Primers (blue triangles) were designed
mature secreted protein. (B) Multiple sequence alignment was performed usin
Samples from 24 animals were analyzed to establish the SCGB1A1P consensus
the SCGB1A1 exon 2 gene sequence showing the three individual single nuc
217) used as internal markers for subsequent gene-specific identification (SCGsites comprising the signature were C/A–G–A, A–A–A,
and A–G–G in SCGB1A1P, SCGB1A1, and SCGB1A1A,
respectively. These differences were subsequently used for
individual SCGB1A1 transcript identification.
Isolation and characterization of SCGB1A1 transcripts
To evaluate the transcriptional state of activation of each
SCGB1A1 gene, end-point limiting dilution (EPLD)-PCR
was performed with serially diluted cDNA preparations
from adult equine lung (n = 3) and uterus (n = 3) tissues.
Tissues were selected on the basis of their strong total
SCGB1A1 transcript expression [11]. Primers were devel-
oped in conserved regions of the genes to avoid gene-
specific preference during the amplification process. Each
PCR assay was performed using a defined amount of an
optimized limiting cDNA concentration as template
(Figure 3A). The dilution that resulted in detectable ampli-
fication in less than 50% of the reactions was considered
to be limiting. At this concentration, the DNA target was
assumed to reflect a Poisson distribution, suggesting thatl SCGB1A1 genomic sequence was amplified by nested PCR using
to target SCGB1A1 exon 2 to 3 (green boxes), coding for the complete
g the nested PCR products from SCGB1A1P, SCGB1A1 and SCGB1A1A.
sequence, and 12 samples for SCGB1A1 and SCGB1A1A. (C) A region of
leotides (arrows) at positions 2217/2242/2284 (cDNA positions 150/175/
B1A1P= C/A–G–A; SCGB1A1 = A–A–A; SCGB1A1A= A–G–G).
Figure 3 End-point limiting dilution PCR strategy. (A) Left: Schematic illustration of EPLD-PCR. Center: Serial cDNA dilutions (ng/μl) were
tested to determine an approximate limiting dilution concentration of template. Right: Each selected limiting dilution was further tested to
confirm the PCR efficiency. Here, 3 out of 7 PCR amplifications were positive for the specific 256-bp amplicon, confirming a <50% expected value
(efficiency = 33%). (B) EPLD-PCR amplicon sequences. Only SCGB1A1 and SCGB1A1A were identified on the chromatograms using the gene-
specific signature (arrows). No SCGB1A1P cDNA was identified. M, 100-bp marker; concentrations are indicated in ng/μL.
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therefore detectable products originated from a single
template.
A total of 212 PCR products were amplified from 665
reactions (32% efficiency) using lung cDNA limiting
dilutions as template (42-124 amplicons/animal). An
additional 86 products were generated from 175 reac-
tions (49% efficiency) using uterine cDNA (28-29 ampli-
cons/animal). Each individual PCR product was purified,
sequenced (forward), and identified by the SCGB1A1 sig-
nature sequences (Figure 3B). In lung samples, 30% of
products were identified as SCGB1A1 cDNA (A–A–A)
and 70% as SCGB1A1A (A–G–G). Likewise, in uterus
samples, 56% were identified as SCGB1A1 and 44% as
SCGB1A1A.
From the 298 amplicons identified, 20 SCGB1A1 and
SCGB1A1A cDNAs were randomly selected for further
characterization. Each sample was re-submitted for se-
quencing in both forward and reverse directions, and
results were aligned to determine the cDNA sequence
delimited by the start and stop codons. Subsequently,
SCGB1A1 and SCGBA1A cDNA consensus sequences
were obtained by alignment of the 20 gene-specific
sequences (accession numbers JQ906259, JQ906260,
JQ906261, Additional file 1: Figure S1). As expected,
strict nucleotide identity was observed between an indi-
vidual cDNA and the corresponding genomic sequence.
However, several disagreements were observed uponcomparison with the predicted EquCab2.0 cDNA
sequences. Among samples in this study, the partial
SCGB1A1 cDNA consensus sequences displayed a non-
conservative substitution at position 19 (A to G) and two
variable codons (Variant A, TTA or variant B, CTC) at
positions 232 to 234. The latter variants both code for the
production of a leucine residue. Similarly, our SCGB1A1A
consensus sequence showed 5 non-conservative substitu-
tions at position 65 (A to G), 78 (C to A), 81 (T to G), 175
(A to G), and 217 (A to G) compared to the EquCab2.0
SCGB1A1A predicted cDNA sequence. Single-nucleotide
insertions or deletions were not detected.
Surprisingly, SCGB1A1P cDNA was not detected by
EPLD-PCR. Since complete genomic/cDNA nucleotide
identity was observed for SCGB1A1 and SCGB1A1A,
SCGB1A1P similarly was assessed using the predicted
cDNA sequences extracted from EquCab2.0 and our con-
sensus genomic sequences (accession numbers JQ951929,
JQ951930, JQ951931, Additional file 1: Figure S1). Ana-
lysis revealed 98% pairwise identity between the predicted
cDNA and the genomic DNA (272/276 nucleotides).
Three non-conservative substitutions were identified at
positions 14 (T to G), 19 (G to A), and 220 (A to T). Most
strikingly, the A to T substitution detected at position 220
in the variant sequences B and C represented 54% of the
horses analyzed (13/24), independent of their genetic
background. This polymorphism is expected to replace an
AAG codon encoding lysine, to a TAG codon, encoding a
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ence of a SCGB1A1P gene variant that may encode a trun-
cated protein in a large proportion of animals.
SCGB1A1 copy- and tissue-specific expression pattern
Expression of SCGB1A1 and SCGB1A1A specific mRNA
was investigated by semi-quantitative reverse transcriptase
(sqRT)-PCR in tissues from seven adult horses (two geld-
ings, three mares and two stallions, Figure 4). This tech-
nique was selected to survey the expression pattern rather
than determine precise expression levels, since a high de-
gree of SCGB1A1 variation was expected between differ-
ent tissues. The results were categorized into three groups
based on the amount of specific PCR product detected by
density scanning after gel electrophoresis. A relative op-
tical density (OD) value was attributed to each band, usingFigure 4 Representative sample of sqRT-PCR evaluation of SCGB1A1 t
SCGB1A1A (label “A”) cDNAs were detected as 200 bp amplification bands.
Densely stained amplicons of SCGB1A1 and SCGB1A1A cDNA were detected
bands were present in multiple tissues including brain, pituitary, eye, nose
spleen, small and large intestine, adrenal gland, kidney, skin, bladder, ureth
products were detected with cDNA from the eyelid gland, thyroid, bone m
intestine; EG, eyelid gland; NE, Nose epithelium; SG, salivary gland; CM, cardglyceraldehyde dehydrogenase (GAPDH) amplicons as the
reference value (Table 1).
Results in the first group corresponded to cDNA sam-
ples that generated abundant PCR amplicons with high
OD (>0.50) for both SCGB1A1 genes. Samples from
lung, uterus (non-pregnant), Fallopian tube, and mam-
mary gland (non-lactating) consistently and reproducibly
met this criterion.
The second group included cDNAs that produced a
faint PCR product for either SCGB1A1 or SCGB1A1A,
and had relatively low (0.01 to 0.50) OD values. Brain,
pituitary gland, eye, nose epithelium, tongue, parotid sal-
ivary gland, trachea, aorta, liver, spleen, small and large
intestine (cecum), adrenal gland, kidney, skin, bladder,
urethra, prostate, epididymis, seminal vesicle, testis and
ovary were included in this group.ranscript levels in various equine tissues. SCGB1A1 (label “1”) and
Equine GAPDH (label “G”) was amplified as an internal control (254 bp).
in lung, uterus, Fallopian tube and mammary gland tissues. Faint
epithelium, tongue, salivary gland, trachea, aorta, cardiac muscle, liver,
ra, prostate, epididymis, seminal vesicle, testis and ovary. No PCR
arrow, pancreas, stomach and lymph node. SI, small intestine; LI, large
iac muscle; LN, lymph node; BM, bone marrow; SV, seminal vesicle.
Table 1 Semi-quantitative analysis of SCGB1A1 RT-PCR amplicons
Relative amplicon density
Expression category Tissue GAPDH SCGB 1A1 SCGB 1A1A n
High Lung 1.00 3.50 ± 0.94 3.65 ± 0.72 5
Uterus 1.00 2.25 ± 0.59 2.02 ± 0.61 4
Fallopian tube 1.00 2.67 ± 1.60 1.49 ± 1.59 3
Mammary gland 1.00 0.67 ± 0.67 nd - 0.33 3
Ovary 1.00 nd - 0.65 nd - 0.07 3
Prostate 1.00 nd - 1.67 nd 2
Low Aorta 1.00 0.42 ± 0.55 nd - 0.32 4
Urethra 1.00 0.25 ± 0.38 0.01 ± 0.01 4
Epididymis 1.00 nd - 0.07 0.16 ± 0.20 2
Skin 1.00 nd - 0.49 0.04 ± 0.01 4
Trachea 1.00 nd - 0.19 0.81 ± 0.73 4
Eye 1.00 nd - 0.26 nd - 0.43 4
Brain 1.00 0.09 ± 0.08 0.08 ± 0.02 4
Nose epithelium 1.00 nd - 0.17 0.04 ± 0.03 4
Bladder 1.00 0.06 ± 0.04 nd - 0.03 4
Spleen 1.00 nd - 0.07 nd - 0.04 4
Kidney 1.00 nd - 0.02 nd - 0.01 4
Liver 1.00 nd - 0.02 nd - 0.01 4
Tongue 1.00 nd - 0.05 nd 3
Small intestine 1.00 0.02 ± 0.01 nd 4
Large intestine 1.00 0.03 ± 0.02 nd 4
Pituitary 1.00 nd - 0.01 nd - 0.02 4
Salivary gland 1.00 nd - 0.01 nd 4
Adrenal gland 1.00 nd - 0.01 nd 4
Seminal vesicle 1.00 nd - 0.42 nd 2
Testis 1.00 nd 0.02 ± 0.01 2
Absent Eyelid gland 1.00 nd nd 4
Cardiac muscle 1.00 nd nd 4
Thyroid 1.00 nd nd 4
Stomach 1.00 nd nd 4
Pancreas 1.00 nd nd 4
Lymph node 1.00 nd nd 4
Bone marrow 1.00 nd nd 3
Quantification of gene-specific SCGB1A1 cDNA amplicon intensity relative to GAPDH using Image Lab™ software 2.0.1; nd, non-detected.
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gel-detectable PCR amplicons for any sample tested, and
therefore, were unsuitable for quantitative assessment.
Eyelid gland, thyroid, bone marrow, cardiac muscle, pan-
creas, stomach and lymph node were considered nega-
tive for SCGB1A1 expression.
Quantification of SCGB1A1 gene-specific expression level
To gain insight into the role of SCGB1A1 genes in the
pathogenic mechanisms of RAO, we next sought todetermine gene-specific expression in the lung, based
on the previous observation that total SCGB1A1 gene
expression levels were reduced in affected animals [6].
Relative transcript levels were determined by quantita-
tive RT-PCR (qRT-PCR) using gene-specific primers
for SCGB1A1 and SCGB1A1A (Figure 5A). Both equine
GAPDH and 18S genes were amplified concurrently
for use as internal standards, and all PCR products
were analyzed by gel electrophoresis and melting curve
analysis (Figure 5B-D). Lung tissues from clinically
Figure 5 SCGB1A1 and SCGB1A1A qRT-PCR strategy. (A) Multiple sequence alignment of the partial predicted SCGB1A1 and SCGB1A1A
EquCab2.0 genomic sequences as well as the SCGB1A1 and SCGB1A1A sequences derived in this study. Two gene-specific primer sets (blue
arrows) were designed at sites with the greatest amount of sequence variation (colored annotations above primers). Forward primers are
positioned in exon 2 (long green arrow) and reverse primers in exon 3 (small green arrow). This region covers position 2,144 to 2,647 of SCGB1A1
genes corresponding to a 504 bp genomic DNA section (brackets). (B) As expected, SCGB1A1 was detected as a 200 bp PCR product using lung
cDNA as a template (Lane 1), a 504 bp band using genomic DNA as template (Lane 2), and undetected with template omission (negative control,
Lane 3). Similar findings were noted for SCGB1A1A (Lane 4, 5, and 6, respectively). (C) qRT-PCR products were analyzed after electrophoresis to
assure cDNA quality and confirm the absence of genomic DNA contamination. Bands were expected at 203 bp for equine 18S (Lane 1), 254 bp
for GAPDH (Lane 2), 200 bp for SCGB1A1 (Lane 3) and SCGB1A1A (Lane 4). (D) Melting curve analysis shows distinct SCGB1A1 and SCGB1A1A
melting temperatures of 86.7°, and 87.6° respectively, indicating gene-specific amplification. M, 100-bp marker.
Figure 6 SCGB1A1 and SCGB1A1A expression analysis in lung
tissues from control and RAO horses. Quantification of SCGB1A1
and SCGB1A1A RT-PCR products was relative to both equine GAPDH
and ribosomal 18S gene expression levels. Values are displayed as
SCGB1A1A/SCGB1A1 ratios. In control horses, the gene expression
ratios were consistently and significantly lower compared to those
of age-matched RAO horses (2.4 ± 0.2, n = 9 vs 5.1 ± 1.4, n = 5,
respectively). Lung biopsies from RAO animals were from either
exacerbation or remission periods.
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and the latter group included individuals sampled dur-
ing exacerbation and remission episodes. Results were
reported as the ratio of SCGB1A1A/SCGB1A1 gene
expression.
As shown in Figure 6, similar expression ratios were
detected in the lung of healthy individuals (2.4 ± 0.2, n = 9),
who consistently had slightly higher SCGB1A1A than
SCGB1A1 expression. Comparable expression ratios
were also noted in uterine tissues (2.6 ± 0.7, n = 7, data
not shown), suggesting an equivalent distribution of the
two SCGB1A1 genes in different organs. However, the
SCGB1A1 expression ratio was significantly different
(5.1 ± 1.4, n = 5) in RAO animals compared to control
animals of similar age. Higher ratios were attributable to
increased SCGB1A1A expression, suggesting that main-
tenance of an appropriate SCGB1A1 gene ratio might be
necessary for homeostasis, and that abrogation of the
ratio may contribute to or reflect RAO development.
SCGB 1A1 protein expression
In order to evaluate the correlation between SCGB1A1
gene expression and the distribution of the protein,
Figure 7 Immunohistochemical identification of SCGB 1A1
proteins. SCGB 1A1 proteins were detected in distal lung bronchioles
(A), uterine glands (B), and Fallopian tube (C). Inserts are sections
incubated with pre-immune serum instead of primary antibody. Note
that not all cells within each epithelial layer express SCGB 1A1.
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try using the previously described antibody to equine
SCGB 1A1 [6]. This antibody was generated against a
SCGB 1A1 peptide, which is shared by both SCGB 1A1
and SCGB 1A1A, and therefore was expected to label both
predicted SCGB 1A1 proteins. Detailed examination of
lung tissue revealed strong and specific SCGB 1A1 staining
of the majority of non-ciliated cells lining the smaller bron-
chi and bronchioles (Figure 7A). The cytosolic signal was
diffuse and did not show basal or apical predilection. SCGB
1A1 staining intensity was highest in the small bronchiolar
ducts, suggesting greater expression in the distal bronchi-
olar tree. Diffuse faint staining was noted among intrab-
ronchiolar secretions. Other pulmonary components such
as blood vessels, fibroblasts, alveolar epithelium, goblet and
basal cells, did not stain for SCGB 1A1.
Analysis of the extra-pulmonary tissues revealed that
epithelial cells in the uterus, ovary, Fallopian tube and
mammary gland also expressed SCGB 1A1. Within the
uterus, large coiled glands composed of columnar epithe-
lial cells stained most strongly positive (Figure 7B), while
in the ovary only epithelium from the wall of residual cysts
showed some degree of staining, and luteal cells were
negative. The ciliated cells of the Fallopian tube stained
positive, with a strong apical signal extending to the cilia
(Figure 7C). Immunoreactive SCGB 1A1 was not detected
in pancreas, liver, kidney, adrenal gland, large intestine,
striated and smooth muscle, duodenum, adipose tissue,
nerve, nose epithelium, skin, stomach, aorta, cartilage,
bone marrow, brain and pituitary gland.
Discussion
In this study we report the identification and
characterization of three equine SCGB1A1 genes. A large
segment of genomic sequence was amplified for each
SCGB1A1 gene and the partial coding sequences leading
to the mature secreted proteins were sequenced. We
found that certain nucleotides from each of the three
genes differed from the other two genes, and that this pat-
tern was conserved amongst individuals. The distinct
SCGB1A1 genes were predicted to produce slightly differ-
ent proteins, and were therefore referred to as SCGB1A1P,
SCGB1A1 and SCGB1A1A based on the recommended
systematic gene nomenclature system [20]. A non-
contiguous region composed of three distinct nucleotide
variants was chosen as a signature sequence to generate
assays specific for each individual SCGB1A1 gene.
Analysis of the predicted SCGB1A1 sequences
extracted from EquCab2.0 (NCBI) revealed more than
90% pairwise identity between SCGB1A1P, SCGB1A1,
and SCGB1A1A genes, including large segments of 5’-
and 3’-flanking regions. This high level of sequence iden-
tity between both the coding and non-coding regions of
SCGB1A1 genes created a challenge for isolation andassessment of individual genes. Thus, more than 10 kb
of non-coding sequence surrounding each SCGB1A1
gene was interrogated to identify anchor regions for
gene-specific primers. Primers selected included at least
three nucleotides unique to each SCGB1A1 gene.
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cation of desired targets with lack of cross-amplification.
Comparative analysis of the coding region of SCGB1A1
genes revealed some disparity with the predicted
EquCab2.0 sequences. Our sequences differed at three
positions in SCGB1A1P, one position in SCGB1A1, and
five positions in SCGB1A1A, corresponding to 1.1, 0.4,
and 1.8% of difference, respectively. These differences may
result from copy number variants and chromosomal rear-
rangements hindering automated sequence assembly of
the equine genome [21]. This is consistent with recent
studies reporting equine chromosome 12 as a “hotspot”
for genomic rearrangements, such as enrichment in copy
number variants and single nucleotide polymorphisms
(SNP) [22,23]. A SNP was detected in SCGB1A1P and two
SNPs in SCGB1A1, but neither affected the predicted
translated products. Altogether, we identified several se-
quence differences to the EquCab2.0 genome, which high-
lighted the importance of developing gene-specific assays.
The three SCGB1A1 genes had similar gene structure
and highly conserved intron/exon organization, suggest-
ing that each contained all the elements required for ex-
pression. Thus, the transcriptional state of each gene
was evaluated by EPLD-PCR. SCGB1A1 and SCGB1A1A,
but not SCGB1A1P, were specifically detected in EPLD
of lung and uterus. These results are consistent with de-
tection of two differently migrating SCGB 1A1 proteins
in uterine washes from mares in early pregnancy [18].
Furthermore, the sequence of each gene between start
and stop codon was identical to our genomic sequence.
The equine genome draft was derived from DNA of a
single Thoroughbred mare, while our EPLD-PCR data
were generated from animals of various genetic back-
grounds and may thus be more representative of this
challenging genome region.
SCGB1A1P transcripts were not detected in lung or
uterine tissue. Reasons for lack of SCGB1A1P gene tran-
scription were unclear, especially since the gene struc-
ture is virtually identical to that of the other SCGB1A1
genes. However, the SCGB1A1P sequence was more
variable between individuals, had a shorter promoter re-
gion (which may imply lack of regulatory elements) and
contained a putative stop mutation in a significant per-
centage of individuals. These characteristics suggest that
SCGB1A1P may be a pseudogene.
The non-synonymous nucleotide variations observed
between SCGB1A1 and SCGB1A1A result in 12 amino
acid (AA) substitutions among the 70 residues of the
mature secreted proteins. Seven of the variable AAs are
concentrated between position 26 and 36 (protein in-
cluding the signal peptide). This region borders the
SCGB 1A1 central cavity that binds hydrophobic ligands
(reviewed in [24]), and AA with hydrophobic properties
comprise the cavity [25]. Since some conserved AA,such as phenylalanine 27 (F27), also have ligand-binding
properties, substitution of F27 to L27 in SCGB 1A1A
suggests 1) a change in ligand-binding specificity, and 2)
that SCGB 1A1 and 1A1A may have independently
evolved to bind distinct substrates. Other substitutions
in this region largely maintain hydrophobic properties
(A28 to V28, I31 to V31, G33 to A33, F35 to Y35), im-
plying minor change in ligand affinity. There is high se-
quence identity in other regions of each protein with
preservation of critical structural residues such as C24
and C90 needed for homodimer interaction, and K63,
D67 and A58 required for protein stability. However,
also of interest, the predicted isoelectric point (pI) of
SCGB 1A1 and 1A1A proteins are 5.1 and 6.3, respect-
ively, which corresponds to the SCGB1A1 variants
described in uterine washes of pregnant horses [18].
The spectrum of tissues expressing SCGB1A1 has not
been extensively studied in horses. Expression nonspeci-
fic for individual genes was previously identified in lung,
uterus and prostate, and absent in liver, kidney, heart,
spleen, as well as thyroid, pituitary and adrenal gland
tissues by Northern blot analysis [11]. We selected a gene-
specific RT-PCR approach to characterize the distribu-
tion of SCGB1A1 and SCGB1A1A transcripts in a total
of 33 tissues. This assay amplified the coding region of
the entire mature protein (second and third exons) to
reduce potential genomic DNA targeting, and specificity
was verified by random purification and sequencing of
amplicons. As expected, SCGB1A1 and SCGB1A1A
transcripts were strongly detected in lung and uterus,
but also in Fallopian tube and mammary gland tissue.
Fewer transcripts of either gene were present in brain,
pituitary gland, eye, nose epithelium, tongue, salivary
gland, trachea, aorta, liver, spleen, small and large intes-
tines, adrenal gland, kidney, skin, bladder, urethra, pros-
tate, epididymis, seminal vesicle, testis and ovary, and
no transcripts were detected in eyelid gland, thyroid,
bone marrow, cardiac muscle, pancreas, stomach and
lymph node. Detection of transcripts in a greater range
of tissues by PCR than by Northern blotting may reflect
higher sensitivity of the former, and greater specificity
due to exact primer match. Some tissues had more of
one relative to the other gene product, suggesting
tissue-specific expression patterns. While the regulatory
mechanisms that could selectively drive the expression
of individual SCGB1A1 genes remain to be elucidated,
this finding is consistent with unique functions of dif-
ferent SCGB 1A1 proteins.
Immunohistochemical analyses were carried out to
evaluate the correlation of SCGB1A1 gene and protein ex-
pression, and to determine cell-specific expression within
tissues. The antibody employed recognized an epitope
shared by all SCGB 1A1 proteins. Strong staining was
detected in tissues expressing the highest number of
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mary gland. However, within these tissues, SCGB 1A1 was
present in only specific epithelial cell populations, and ab-
sent in all other cell types (Figure 7). This distribution
likely contributed to variation of SCGB1A1 transcript in-
tensity, since the proportion of epithelial cells and sub-
types in tissues selected was variable [26].
SCGB 1A1 may be selectively taken up and targeted
for degradation upon binding to a transmembrane pro-
tein called cubilin [27]. Interaction of SCGB 1A1 with
lipocalin-1 interacting membrane receptor (LIMR) has
also been reported, but the effect of this interaction is
unclear [28]. Of note, LIMR is expressed in tissues posi-
tive for SCGB1A1 transcripts, including lung, mammary
gland, trachea, prostate, testis, pituitary gland, adrenal
gland, cerebellum, kidney, and colon [29]. SCGB 1A1
protein was not detected in tissues with low transcript
expression such as bladder, trachea, liver, nose epithe-
lium, pituitary and intestine. Possible reasons are lesser
sensitivity of IHC compared to PCR, and transient gene
expression insufficient to produce detectable protein, as
has been reported in studies of rabbit tissues [30].
Horse and human have a similar pattern of SCGB1A1
transcript distribution in lung [31], uterus [13,32], Fallo-
pian tube [33], prostate [34,35], trachea, thyroid, mam-
mary gland, brain, pituitary, thymus, aorta, heart, stomach,
spleen, adrenal gland, kidney, liver, small intestine, ovary
and testis [36]. In humans, the SCGB1A1 gene was ultim-
ately considered to be ubiquitously expressed in most cells
of epithelial origin and to inactivate inflammatory media-
tors on surfaces exposed either directly or indirectly to the
external environment [37,38]. Conversely, it was also
reported that decreased SCGB1A1 expression could con-
tribute a tumor microenvironment permissive of inflam-
mation and hence tumor progression [38,39].
Since total SCGB1A1 expression was reported as
decreased in RAO, we sought to evaluate if both
SCGB1A1 and SCGB1A1A genes were similarly affected.
Our analysis demonstrated that the ratio of SCGB1A1A/
SCGB1A1 was significantly different in RAO affected-
animals compared to controls. This finding may arise as
a result of chronic inflammation with preferential tran-
scription of SCGB1A1A, or may signal inherent differ-
ences in transcriptional regulation of SCGB1A1 genes.
Segregation analysis previously revealed a complex gen-
etic background influencing expression of the RAO
phenotype [40]. SCGB1A1 was among candidate genes
[10], suggesting that further evaluation of specific gene
expression may be warranted. The latter observation also
raises the question whether SCGB1A1 genes are con-
trolled by different regulatory mechanisms and whether
they have different physiological functions. Such hypoth-
eses are difficult to address due to the absence of mul-
tiple SCGB1A1 copies in other mammals except otherequidae, such as donkeys and Przewalski horses (unpub-
lished data). SCGB1A1 isoforms in equid species remain
to be characterized, but may yield insight into SCGB1A1
gene origin and ancestral gene triplication.
Conclusions
Three equine SCGB1A1 genes were isolated and charac-
terized. SCGB1A1P appears to have evolved into a pseudo-
gene, which no longer generates a detectable transcript
and includes a non-sense mutation in the majority of ani-
mals. The distribution of SCGB1A1 and SCGB1A1A gene
transcripts and proteins indicates highly specific expres-
sion in specialized epithelial cells of lung and reproductive
organs. Gene specific assessment of transcripts showed
approximately 2.5 fold higher expression of SCGB1A1A
than SCGB1A1 in lung and uterus of control animals, and
an increased ratio in lung tissue of animals with RAO, an
asthma-like condition. Future studies will assess the func-
tion of different SCGB 1A1 proteins and attempt to eluci-
date their anti-inflammatory properties.
Methods
Samples
Animal procedures were approved by the University of
Guelph Animal Care Committee (Protocol R10-031) and
conducted in compliance with guidelines of the Canadian
Council on Animal Care. All horses belonged to the in-
stitutional research herd; horses with and without RAO
were of similar age ranging from 12 to 20 years. Horses
with RAO had a history of recurrent cough, difficulty
with exhaling air, and neutrophilic inflammation in
BAL fluid samples. Control horses had no history of
lung disease, had normal physical exam findings, and
no abnormalities on airway bronchoscopy or pulmon-
ary function testing, as described before [6].
Horses were restrained in stocks and percutaneous lung
biopsies were obtained under sedation with romifidine
(10 mg/mL, IV), as previously described [6]. Samples were
immersed in RNAlater™ solution (Qiagen, Mississauga,
ON) and stored at -80°C until RNA preparation.
SCGB1A1 gene identification and localization
SCGB1A1 sequences were obtained from the National
Center for Biotechnology Information (NCBI) database.
Alignment of the Equus caballus chromosome 12 gen-
omic contig (EquCab2.0) [GenBank: NW_001867370.1]
[19] and the equine secretoglobin precursor mRNA
[GenBank: AY885564.1] was performed through a nucleo-
tide megablast analysis for highly similar sequences using
the following parameters: expected threshold, 10; word
size, 16; match-mismatch scores, 1, -2; gap cost - linear;
filter - low complexity. Further data processing, including
sequence extractions, multiple sequence alignments, and
statistical analysis, were accomplished with Geneious Pro
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minor manual adjustments [41].
Isolation and characterization of SCGB1A1 genomic
sequences
Blood samples or buccal swabs were available from 24 adult
horses including 6 breeds (Standardbred, Thoroughbred,
Icelandic, Canadian sport, Lipizzaner, and Quarter horses)
and animals of mixed breeding. Genomic DNA was
extracted according to the manufacturer’s protocol (DNA
Mini kit, Qiagen). LR-PCR primers were as follows:
SCGB1A1P primer forward UG1-F (50-ACA GAG CCA G
CC CAA GCA ATG-30) and reverse UG1-R (50-GAT TAC
CTT GGC GGT TGC CTA GAG-30), SCGB1A1 primer
forward UG2-F (50-CAC CTA ACA GCC TCA TCT C-30)
and reverse UG2-R (50-GTG AGA GCT CTC ATC TGG
TA-30), and SCGB1A1A primer forward UG3-F (50-ACA
CAG ATC TGA TGC CCA AG-30) and reverse UG3-R
(50-AGT GCA GCT CTC TCA GGC AT-30), amplifying
5559, 6029, and 5442 bp of genomic DNA, respectively.
Primers were obtained from Sigma-Aldrich (Burlington,
ON). LR-PCR amplifications were carried out using a
Platinum Taq polymerase PCR kit (Invitrogen, Missis-
sauga, ON). Each reaction was performed in a final
volume of 50 μL, including 5 μL of 10X PCR buffer,
0.2 mM dNTPs, 2 mM MgSO4, 0.3 μM of each pri-
mer, 2 U of Platinum Taq, and 5 μL of template DNA
(100 ng). Conditions for amplification were 1 min at 94°C
followed by 35 cycles of 94°C for 30 s; gene-specific
annealing T°C for 30s; and 68°C for 6:30 min, followed by
final elongation for 10 min at 68°C. Gene-specific anneal-
ing temperatures for SCGB1A1-1, -2, and -3 were 62°C,
55°C and 60°C respectively. Twenty μL of each PCR
product was separated by electrophoresis in a 1% agar-
ose gel stained with SYBR Safe (Invitrogen). The ampli-
fied DNA bands were cut out and the DNA was
extracted, purified (QIAquick, Qiagen) and quantified
using a NanoDrop 2000 photometer (Thermo Fisher
Scientific, Mississauga, ON). To validate the gene-
specificity of the PCR products, each purified DNA frag-
ment was digested with HindIII (Invitrogen), separated
by electrophoresis and monitored for the appropriate
digestion pattern.
A genomic DNA band of 526 bp coding for the
full-length mature secreted protein (exon 2 to 3) was
amplified by nested PCR using LR-PCR purified DNA pro-
ducts as template and the forward UGn-F (50-GCT TCT
GCA GRA ATC TGC CAG AG-30) and reverse UGn-R
(50-CTA AGC ACA CAG TGG GCT CTY TRC-30) pri-
mers. PCR amplifications were carried out in duplicate
using the Taq DNA polymerase Native PCR kit (Invitrogen)
in a final volume of 25 μL of PCR buffer (2 μL of 10X PCR
buffer, 1.0 mM dNTP, 1.5 mM MgSO4, 0.6 μM forward
and reverse primers, 1 unit Platinum Taq, and 1 μL oftemplate DNA). Cycling conditions were 1 min at 94°C fol-
lowed by 30 cycles of 94°C for 30 s; 62°C for 30 s; and 72°C
for 90 s with a final elongation of 7 min at 72°C. Twenty μL
of each PCR product was subjected to electrophoresis;
bands of appropriate size were excised from the gel, puri-
fied and submitted for automated sequencing (Laboratory
Services Division, Guelph, ON). Amplicons were analyzed
in duplicate using reverse and forward primer sequencing
strategies. The consensus sequence for each copy was
determined using multiple sequence alignments.
Detection of distinct SCGB1A1 transcripts
Total RNA was isolated from fresh or frozen lung and
uterus tissues (RNeasy, Qiagen) according to the man-
ufacturer0s recommendations. RNA integrity was verified
through capillary electrophoresis in a 2100 Bioanalyzer
(Agilent Technologies) prior to analysis. Complementary
DNA (cDNA) was synthesized following the Superscript
III Reverse Transcriptase kit0s protocol (Invitrogen), with
an additional 15 min DNAse I treatment (Qiagen) at
room temperature. A cDNA band of 256 bp delimited
by the start (ATG) and termination (TAG) codon within
each of the SCGB1A1 genes was targeted with the fol-
lowing primers: forward UGm-F (50-GTC CAC CAT
GAA ACT CGC CA-30) and UGm-R (50-CTA AGC
ACA CAG TGG GCT C-30). End-point limiting dilution
(EPLD)-PCR assays were performed in a volume of
25 μL of PCR reaction mix (2 μL of 10X PCR buffer,
1.0 mM dNTP, 1.5 mM MgCl2, 0.6 μM forward and re-
verse primer, 1 unit of Platinum Taq and 1 μL of tem-
plate cDNA). A broad range of serially diluted cDNA
concentrations was tested (0.25 to 0.000156 ng/μL) to
determine the optimal limiting-dilution for each sam-
ple (0.0005 to 0.0006 ng/μL). PCR products were sepa-
rated by electrophoresis, purified, sequenced and
identified via their SCGB1A1 gene-specific signature
sequences.
Tissue-specific expression of SCGB1A1
SCGB1A1 and SCGB1A1A relative transcript levels were
evaluated by semi-quantitative reverse transcriptase-PCR
(RT-PCR) in 33 different tissues from normal adult
horses including cortical brain, pituitary, eye, nose epi-
thelium, tongue, thyroid, trachea, lung, aorta, cardiac
muscle, liver, spleen, small and large intestine, stomach,
kidney, pancreas, skin, bladder, urethra, prostate, epi-
didymis, seminal vesicle, testis, uterus, ovary, Fallopian
tube, bone marrow, lymph node, as well as mammary,
salivary, adrenal and eyelid glands. Total RNA isolation
and cDNA synthesis were performed as described above.
A specific cDNA band of 200 bp was amplified for each
SCGB1A1 gene using the following primers: SCGB1A1
forward UGrt-2 F (50-GCT TTG CAG ACA TCA TTC
AAG GCC-30) and reverse UGrt-2R (50-CTA AGC ACA
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ward UGrt-3 F (50-GAT TKG TAG GCA TCG TTC
AAG CCC-30) and reverse UGrt-3R (50-CTA AGC ACA
CAG TGG GCT CTC TA-30). A 254 bp equine glyceral-
dehyde dehydrogenase (GAPDH) gene product served as
an internal control using forward GAP-F (50-GTT TGT
GAT GGG CGT GAA CC-30) and reverse GAP-R (50-TTG
GCA GCA CCA GTA GAA GC-30) primers. PCR amplifi-
cations were carried out using the HotStar Taq Plus PCR
kit (Qiagen) in a 20 μL Master mix (10 μL of 2X PCR buf-
fer, 0.4 μM of copy-specific forward and reverse primers,
and 1 μL of template cDNA). Conditions for amplification
were 5 min at 95°C followed by 30 cycles of 95°C for 30 s;
61°C for 30 s; 72°C for 1 min followed by a final elongation
of 7 min at 72°C. PCR products were analyzed by electro-
phoresis in a 1% agarose gel and stained with SYBR Safe.
PCR-grade water was distributed as template in negative
control reactions. No amplifications were detected in sam-
ples with water instead of template DNA.
Quantification of SCGB1A1 and SCGB1A1A gene
expression
SCGB1A1, SCGB1A1A and GAPDH primers were as
described above. The equine 18S ribosomal RNA gene
was retained as an additional internal control using for-
ward 18S-F (50- ATG CGG CGG GGT TAT TCC-30)
and reverse 18S-R (50-GCT ATC AAT CTG TCA ATC
CTG TCC-3’) primers. Quantitative PCR amplifications
were performed in a Master mix containing 10 μL of
SYBR Green 2X PCR buffer (Qiagen), 8 μL of PCR-
grade water, 0.4 μM of each forward and reverse primer,
and 1 μL of cDNA template (1 ng/μL). Conditions for
amplification were 7 min at 95°C followed by 45 cycles
of 95°C for 15 s; 61°C for 15 s; 72°C for 20 s using a
LightCyclerW 480 instrument (Roche, Montreal, QC).
SCGB1A1 primer specificity and identity of the PCR
products was confirmed with a melting curve (95°C for
5 s; 45 to 95°C; 40°C for 10 s) and sequence analysis, re-
spectively. For each gene, a series of purified cDNA PCR
product dilutions (100, 10, 1, 0.1, 0.01, 0.001 ng/μL) was
amplified and the average crossing point of each dilu-
tion was used to derive a standard curve. SCGB1A1,
SCGB1A1A, GAPDH, and 18S cDNA were amplified in
triplicate for each sample along with standard curve
calibrators. Data were analyzed using LightCyclerW 480
SW 1.5 software (Roche). Statistical analysis was carried
out using Prism5 (GraphPad Software, San Diego, CA).
Immunohistochemistry
Expression of SCGB 1A1 protein was investigated through
immunohistochemical staining of the 33 adult horse tis-
sues described above. Fresh tissues were fixed in 10%
neutral buffered formalin overnight, embedded in paraf-
fin, and sectioned to 5-μm thickness. Sections weredeparaffinized in xylene, rehydrated in graded alcohols
and incubated consecutively for 10 min in Dako en-
dogenous dual enzyme blocker (DakoCytomation),
30 min with Dako protein block (serum-free), 30 min
with SCGB 1A1 primary antibody (1:400 dilution), and
30 min with horseradish peroxidase-labeled secondary
IgG (1:2000, Dako EnVision HRP). Bound antibodies
were detected with Nova Red (Vector Laboratories,
Burlington, ON) chromogen, and slides were counter-
stained with hematoxylin. SCGB 1A1 primary antibody
was raised in a rabbit immunized with a 21mer peptide
[6]. Pre-immune rabbit serum was used for negative
control slides. Images were acquired on a Leica DMRA2
microscope (Leica Microsystems, Concord, ON) using
Open Lab software (PerkinElmer, Waltham, MA).
Statistical analysis
Values were expressed as means ± standard deviations.
Unpaired two-sample Student’s t-test was used for statis-
tical analysis; p ≤ 0.05 was considered significant.
Additional file
Additional file 1: Figure S1. Multiple sequence alignment of SCGB1A1P,
SCGB1A1 and SCGB1A1A cDNA consensus sequences. The sequences
displayed are as follows: predicted SCGB1A1P EquCab2.0, the SCGB1A1P
variant A (JQ951929), variant B (JQ951930) and variant C (JQ951931)
derived in this study (genomic DNA); predicted SCGB1A1 EquCab2.0,
SCGB1A1 variant A (JQ906259) and variant B (JQ906260) determined in
this study (cDNA); predicted SCGB1A1A EquCab2.0 and SCGB1A1A
(JQ906261) derived in this study (cDNA). For each cDNA sequence, the
corresponding protein sequence is displayed beneath. Colored
annotations highlight discordant bases and amino acids relative to the
consensus sequence (colored) at the top of the figure.
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